Effectiveness And Economic Evaluation Of RSJN In The Prevention Of Thrombotic Disease Among The Tall Lipemia Groups

Objective:To evaluate safety of clinical application of RSJN and effectiveness and economic amongthe tall lipemia groups compared to aspirin, to provide the theory basis and the data support forhyperlipidemia group preventing thrombotic disease and to discuss RSJN’S reasonable price, toprovide reference of the price for relevant departments.Methods:650patients with hyperlipidemia were randomly divided into three groups, A group takingRSJN and supporting the diet and exercise therapy, group B taking aspirin and supporting thediet and exercise therapy, group C only supports diet and exercise therapy, observation time for4years, monthly telephone pays return to visit and statistic those who lost to follow-up case, thequestionnaire and related scale were fillout and picked the blood biochemical tests indicators,using relevant chronic disease index and drug economics method to evaluate effectiveness andeconomic evaluation of RSJN in the prevention of thrombotic disease among the tall lipemiagroups.Result:(1)Security:RSJN group, mild adverse reactions occur in5cases with no serious adverse reactions casesand adverse reaction rate was1.29%, which is within national legal limits; Aspirin group, mildadverse reactions occur in6cases with no serious adverse reactions and adverse reaction ratewas4.13%, which also is within national legal limits.(2)Effectiveness:Related chronic disease incidence index of A group and B group were lower than C group,but not significant (P>0.05). A group reduced the incidence density by1.68, reduced themortality density by1.35, reduced thevisiting rate by2.57%and reduced the hospital admissionrate by1.71%compared with C group. B group compared with C group reduced the incidencedensity by1.84, reduced the mortality density by1.17, reduced thevisiting rate by2.18%andreduced the hospital admission rate by1.51%compared with C group. Total cholesterol andtriglycerides level were lower in B group than those in the normal controls (P <0.05)0.4367mmol/l and0.5596mmol/l, which were0.3228mmol/l and0.4287mmol/l A group totalcompared with the controls.(3)Economic characteristics: Cost-effectiveness analysis results show: Each1unit reduction in the incidence density andhospitalization rate, the costs of A group were381.51yuan and547.81yuan compared with Bgroup’s357.06yuan and435.10yuan; Every0.1mmol/l reduction of the total cholesterol andtriglycerides, the costs of A group were198.56yuan and149.51yuan compared with B group’s150.45yuan and117.45yuan. If RSJN price reduced to14.8yuan, A group will receive better costeffect.Cost-benefit analysis results show: Profit value relative is37.87yuan, relative cost is16.06yuan, benefit cost ratio is2.36over than1, then cost benefit of B group is better than A,But RSJN will receive better cost effectiveness when the price is lower than15.25yuanCost-utility analysis results shows:A group need to pay3908.2yuan for a QALYS compared withB group need to pay4562.5yuan, so A group has better cost utility than aspirin group.Conclusion:In the process of clinical medicine RSJN is as good safety as aspirin, it can take a degreehave to reduce the incidence of chronic disease related index and lipid levels among tall lipemiasmall daily dose group (<100mg), In addition, if RSJN’s prices make the appropriateadjustment as the magazine under14.8yuan, RSJN can obtain a better economic value, overall,taking RSJN can achieve good effect and economic value in the prevention of thrombotic diseaseamong the tall lipemia groups.